[ Inside the business ]

AMGN stock analysis

AMGN · Amgen Inc

Biological products, (no diagnostic substances). Growing 8%. Keeps 32¢ of every dollar.

Watch: growth that has stopped speeding up.

The future, in 7 questions

Priced in: 2.4× sales in 5 yrs. Evidence: sales +8% · 32¢ profit/$1.

01 What's priced in?2.4× sales in 5 yrs
Sales now$38.9B
Needed in 5 yrs$95.0B
02 Is the wave rising?Explainable AI · 1.3×
'20'21'22'23'24'2520
#13 of 20 mentioning it
03 Will customers keep buying?Customer Two: 34% of sales
Customer Two 34%Customer One 27%Customer Three 16%Everyone else
Sales +8%, steady
04 Is it scarce?No
PricingBacklogPrepaidSell-outTight
05 More profit per sale?Keeps 32¢ per $1, rising
'21'22'23'24'2532¢
Before running costs: 76% → 67%
06 Can it fund itself?Pays its own way
05 yrsself-funded
Shares +0.4%/yrDebt $54B
07 What could break it?1 to watch
  • Growth peaked

From SEC filings, price and Radar. Not advice.

The record

Early signals

Growth peaked.

Sales growth +6%, +10%, then +8% vs. a year ago.

What could go wrong

Steadier than most.

It has moved 0.5× the market. In the 2008 crisis it fell 16% while the market fell 51%. Debt is heavy.

Speculative check

Self-funding.

Passes every condition: profitable, cash-generating and financially sound.

What they sell

95% Product.

Product 95% · Product and Service, Other 5% (latest quarter)

Where each dollar goes

32¢ profit.

29¢ to make what it sells, 38¢ on research and overhead, 32¢ left over. Revenue $38.9B in the last 12 months.

Its market

1.5× the economy.

The government expects its industry, pharmaceutical and medicine manufacturing, to grow 3.0% a year to 2035, vs. 2.0% for the whole economy.

Market size and share

Your call.

There's no official size for its market. Enter one you trust to see its share, and slide to see what a bigger share would mean.

Life cycle

Maturity.

It earns cash, still invests, and pays back more than it borrows.

Earnings quality

Clean.

Its numbers don't resemble those of past manipulators. Cash covers 128¢ of each $1 of profit.

Competitive advantage

10 of 10 years.

Returns beat its 7.1% cost of capital in 10 of the last 10 years. Gross margin went from 82% to 67%.

Future bets

20% on research.

$7.8B a year on R&D. $2.5B on equipment and buildings.

All figures from Amgen Inc's SEC filings (EDGAR) unless tagged otherwise. Educational only, not investment advice.